News Breaks |
|
|
| September 26, 2012 |
| 16:24 EDT |  | ACUR, PFE | Acura Pharma announces earlier return of development products
Acura Pharmaceuticals (ACUR) announced a letter agreement with Pfizer (PFE) providing for the termination of Pfizer's license to Acura's AVERSION Technology used in three developmental opioid products as of September 26, 2012 and the transfer of those products back to Acura. On July 26, Acura was notified by Pfizer of its intention to terminate the license to the three development products which carried a 12 month notice period under the terms of the companies' 2007 license agreement. The developmental products being returned to Acura are oxycodone hydrochloride with acetaminophen, hydrocodone bitartrate with acetaminophen and a third previously unnamed opioid, all of which utilize Acura's AVERSION technology. The AVERSION Technology utilizes a proprietary mixture of inactive ingredients to discourage tampering of a product for abusive purposes. "We are pleased that Pfizer agreed to an earlier return of these products for development by Acura," said Bob Jones, President and Chief Executive Officer of Acura Pharmaceuticals. |
|
|
News For ACUR;PFE From The Last 14 Days Check below for free stories on ACUR;PFE the last two weeks. |
|
|
| May 24, 2013 |
| 07:20 EDT |  | ACUR | Acura Pharma management to meet with Roth Capital
Meetings to be held in New York/Boston on May 28-30 hosted by Roth Capital. |
|
| May 22, 2013 |
| 08:59 EDT | | PFE | On The Fly: Pre-market Movers
 Subscribe for More Information |
|
| 08:06 EDT | | PFE | Zoetis comments on Pfizer’s split-off plans for remaining interest
Subscribe for More Information |
|
| 08:04 EDT | | PFE | Pfizer announces plan to split-off remainder of Zoetis
Subscribe for More Information |
|
| 08:02 EDT | | PFE | Pfizer announces plan to split-off remainder of Zoetis
Subscribe for More Information |
|
| May 21, 2013 |
| 07:16 EDT | | PFE | Pfizer management to meet with Leerink
Subscribe for More Information |
|
| May 20, 2013 |
| 17:04 EDT | | PFE | Pfizer discontinues phase 3 study of inotuzumab ozogamicin
Subscribe for More Information |
|
| May 17, 2013 |
| 11:09 EDT | | ACUR | Acura Pharma mentioned positively by Seeking Alpha contributor
Reference Link |
|
| May 16, 2013 |
| 08:55 EDT | | PFE | BofA/Merrill's pharmaceuticals analysts hold analyst/industry conference call
Subscribe for More Information |
|
| May 14, 2013 |
| 08:58 EDT |  | ACUR | Acura Pharma initiated with a Buy at Roth Capital
Target $4.50. |
| |
|
|
|
|
